| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024312 |
| Receipt No. | R000027997 |
| Official scientific title of the study | Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. |
| Date of disclosure of the study information | 2017/05/25 |
| Last modified on | 2017/05/25 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. | |
| Title of the study (Brief title) | Effect of febuxostat and inosine on CNS diseases | |
| Region |
|
|
| Condition | ||
| Condition | Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Examine the effects of the combined use of febuxostat and inosine on Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes of HDS-R (Alzheimer's disease), Yahr's classification (Parkinson's disease), EDSS (multiple sclerosis) and ALSFRS-R (amyotrophic lateral sclerosis) by 2-week treatment with febuxostat and inosine |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Japanese with 20 to 80 years of age
2. Patients diagnosed as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis by specialist doctors. |
|||
| Key exclusion criteria | 1. Subjects taking azathioprine or mercaptopurine
2. Subject who has or had renal function disorder. 3. Subject with a history of gout, hyperuricemia or urolithiasis. 4. Subject who has a history of renal disorder. 5. Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 6. Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons. |
|||
| Target sample size | 12 | |||
| Research contact person | |
| Name of lead principal investigator | Naoyuki Kamatani |
| Organization | Tsukuba International Clinical Pharmacology Clinic |
| Division name | Doctors' office |
| Address | 1-21-16 Kan-nondai Tsukuba City, Ibaraki Prefecture |
| TEL | 029-839-1150 |
| kamatani@msb.biglobe.ne.jp | |
| Public contact | |
| Name of contact person | Masanori Suzuki |
| Organization | Tsukuba International Clinical Pharmacology Clinic |
| Division name | Division for Volunteers |
| Address | 1-21-16 Kan-nondai Tsukuba City, Ibaraki Prefecture |
| TEL | 029-839-1150 |
| Homepage URL | |
| m-suzuki@tsukuba-icp.jp | |
| Sponsor | |
| Institute | Tsukuba International Clinical Pharmacology Clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | StaGen Co. LTD |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027997 |